New rules now allow drug manufacturers to launch similar medicines without prior price approval, streamlining market entry. Companies can seek varied prices for drug variants based on packaging and dosage, fostering flexibility. Overcharging liability is now limited to specific distributors if manufacturers prove compliance, easing burdens for many firms. Stricter record-keeping for seven years is also mandated.